Verition Fund Management
APLS

Verition Fund Management’s Apellis Pharmaceuticals APLS Stock Holding History

Verition Fund Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-51,000
Closed -$1.56M – 597
2019
Q4 		$1.56M Buy
+51,000
New +$1.41M 0.03% 330

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Verition Fund Management's APLS Position: Q1 2026 in Review

Verition Fund Management opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2026: 400,000 shares worth $16.1M. The stake represents 0.1% of the portfolio and ranks #194 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in APLS as recently as Q2 2025.

Verition Fund Management first reported a position in APLS in Q4 2019 and has held it in 14 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Verition Fund Management held 400,000 shares of Apellis Pharmaceuticals worth $16.1M as of Q1 2026.
  • Apellis Pharmaceuticals was a new Verition Fund Management position in Q1 2026.
  • Apellis Pharmaceuticals made up 0.1% of Verition Fund Management's portfolio in Q1 2026, its #194 holding.
  • Verition Fund Management first reported a position in Apellis Pharmaceuticals in Q4 2019 and has held it in 14 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.